NCT04241367Completed
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
Source: ClinicalTrials.gov · Last updated 9 Apr 2026
Brief summary (registry, in English)
This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 420 (actual)
- First submitted
- 22 Jan 2020
- Start date
- 28 Mar 2019
- Primary completion date
- 3 Jun 2021
- Lead sponsor
- National Cancer Center, Korea
- Diseases
- Pancreatic cancer, Childhood cancers
- NCT number
- NCT04241367
What you commit to
- Study type: Observational
- Participants enrolled: 420
- From 28 Mar 2019 to the primary completion date, 3 Jun 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients disagree with the study.
Who the study is looking for
- Patients with pathologically confirmed pancreatic adenocarcinoma.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu, Coordinator of this site? Confirm its status | Goyang-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.